L. Noël, ]. J. Churg, J. L. Duffy, and H. Ohtani, Atlas de pathologie rénale Médecine Sciences Publications « Classification of glomerulonephritis based on morphology, Distribution of glomerular IgG subclass deposits in malignancyassociated membranous nephropathy, p.4361, 1973.

. Transpl, . Assoc.-eur, . Ren, K. Assoc, and . Hihara, Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy Lefaucheur et al., « Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association, Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy Malignancy in Membranous Nephropathy: Evaluation of Incidence », pp.574579-15101517, 2004.

J. Bacchetta, L. Juillard, P. Cochat, and J. Bjørneklett, « Long-term risk of cancer in membranous nephropathy patients, Paraneoplastic glomerular diseases and malignancies, pp.3958-396403, 2007.

A. Schieppati, « Prognosis of untreated patients with idiopathic membranous nephropathy, N. Engl. J. Med, vol.329, issue.2, p.8589, 1993.

N. M. Tomas, Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy, New England Journal of Medicine, vol.371, issue.24, pp.24-22772287
DOI : 10.1056/NEJMoa1409354

N. M. Tomas, Autoantibodies against thrombospondin type 1 domain???containing 7A induce membranous nephropathy, Journal of Clinical Investigation, vol.126, issue.7, p.25192532, 2016.
DOI : 10.1172/JCI85265DS1

URL : http://europepmc.org/articles/pmc4922694?pdf=render

L. H. Beck, « M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy, N. Engl. J. Med, vol.361, issue.1, p.1121, 2009.

H. Dai and H. Zhang, He, « Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis, Sci. Rep, vol.5, 2015.

A. S. De-vriese, R. J. Glassock, K. A. Nath, S. Sethi, and F. C. Fervenza, A Proposal for a Serology-Based Approach to Membranous Nephropathy, Journal of the American Society of Nephrology, vol.28, issue.2, p.421430, 2017.
DOI : 10.1681/ASN.2016070776

E. Hoxha, « Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody negative patients with membranous nephropathy, Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. -Eur. Ren. Assoc, vol.30, issue.11, p.18621869, 2015.

E. Hoxha, A Mechanism for Cancer-Associated Membranous Nephropathy, New England Journal of Medicine, vol.374, issue.20, pp.20-19951996, 2016.
DOI : 10.1056/NEJMc1511702

E. Hoxha, An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain???Containing 7A???Specific Antibodies in Membranous Nephropathy, Journal of the American Society of Nephrology, vol.28, issue.2, p.520531, 2017.
DOI : 10.1681/ASN.2016010050

«. Rituximab-for-severe-membranous and . Nephropathy, A 6-Month Trial with Extended Follow-Up. -PubMed -NCBI ». [En ligne]. Disponible sur: https, Consulté le, pp.12-2017

Y. Chen, Immunosuppression for membranous nephropathy, The Lancet, vol.381, issue.9884, p.787796, 2013.
DOI : 10.1016/S0140-6736(13)61435-X

C. Ponticelli, « A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy, J. Am. Soc. Nephrol, vol.9, issue.3, p.444450, 1998.

C. Ponticelli, A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy, Kidney International, vol.48, issue.5, p.16001604, 1995.
DOI : 10.1038/ki.1995.453

V. Jha, A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy, Journal of the American Society of Nephrology, vol.18, issue.6
DOI : 10.1681/ASN.2007020166

M. Tasaki, A. Shimizu, I. Hanekamp, R. Torabi, V. Villani et al., Rituximab Treatment Prevents the Early Development of Proteinuria following Pig-to-Baboon Xeno-Kidney Transplantation, Journal of the American Society of Nephrology, vol.25, issue.4, p.737744, 2014.
DOI : 10.1681/ASN.2013040363

A. Fornoni, Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis, 85ra46, juin 2011. SERMENT D'HIPPOCRATE @@@@@@@@@@@@@@@@@@ @@@@@@@@@@@@@@@@ RESUME @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@ @@@@@@@@@@@@@@@@@ @@@@@@@@@@@@@@@@@ @@@@@@@@@@@@@@@@
DOI : 10.1074/jbc.272.21.13793